RxDoctor Payments Data

Henry Parkman, MD

Gastroenterology · Philadelphia, PANPI 1770501975

Payments from drug & device makers

$109,712in general payments, 2019–2025

Across 35 payments — averaging $3134.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$47K
  • Takeda Pharmaceuticals U.S.A., Inc.$38K
  • Evoke Pharma, Inc.$18K
  • Enterra Medical, Inc.$4K
  • Ardelyx, Inc.$2K
  • Ironwood Pharmaceuticals, Inc$1K
  • plus $225 from 3 others

What the payments were for

  • Consulting fees$8,05030%
  • Speaking & faculty fees$16,75463%
  • Travel & lodging$8123%
  • Food & beverage$7953%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,712 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,403
Medicare patients
445
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aprepitant290$645,912
SancusoGranisetron173$450,089
RelistorMethylnaltrexone Bromide39$168,287
LinzessLinaclotide152$106,712
CreonLipase/Protease/Amylase71$93,451
XifaxanRifaximin17$78,267
MotegrityPrucalopride Succinate106$75,606
ZenpepLipase/Protease/Amylase12$35,885
MovantikNaloxegol Oxalate75$35,380
Erythromycin Ethylsuccinate47$16,606
TrulancePlecanatide20$14,068
Dexlansoprazole DrDexlansoprazole29$13,964
Pantoprazole Sodium259$7,420
Ondansetron OdtOndansetron350$6,105
ErythromycinErythromycin Base11$5,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Cumberland Pharmaceuticals, Inc.Sancuso$99$450,089173 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$38,155$75,606106 claims
Redhill Biopharma Inc.Movantik$28$35,38075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →